Adverse events following immunization against SARS-CoV-2 (covid-19) in the state of Minas Gerais
DOI:
https://doi.org/10.11606/s1518-8787.2021055003734Keywords:
Coronavirus Infections, prevention & control, Vaccines, adverse effects, Clinical Trials Data Monitoring CommitteesAbstract
OBJECTIVE To analyze adverse events following immunization (AEFI) against SARS-CoV-2 (covid-19) in the state of Minas Gerais (MG), Brazil. METHODS Epidemiological, descriptive study, with data from e-SUS Notifica (e-SUS Notification) in the state of Minas Gerais from January 20 to March 5, 2021. All suspected cases of AEFI of the covid-19 vaccine in the state were analyzed, totaling 7,305 cases. In this study, we verified the possible correlation between AEFI and the possible immunobiological administered causalities. The variables analyzed for AEFI cases were the immunobiological agent administered (AstraZeneca or Coronavac), the type of event, the evolution of the case, and the time in days since the administration of the immunobiological agent and the onset of symptoms and causality. The incidence rate (IT) was calculated for 100,000 doses applied. RESULTS The occurrence of AEFI as a result of the covid-19 vaccine was frequent (TI: 777.12) in the state. However, only 3% were classified as a severe AEFI, with a 20.85 IT, and 4.71% of them evolved to deaths (8.19 deaths per 100,000 doses applied). Among the deaths analyzed, 84.4% were classified as preexisting conditions caused by factors other than vaccines. Regarding non-serious AEFI, 1.11% occurred by immunization errors (TI: 8.62 EI for every 100 thousand doses applied). CONCLUSION This work encourages the discussion about the importance of recording AEFI related to covid-19 vaccines, demonstrating its safety for the population.
References
Zhu N, Zhang D, Wang W, Li X, Yang B, Song J, et al. A novel coronavirus from patients with pneumonia in China, 2019. N Engl J Med. 2020;382(8):727-33. https://doi.org/10.1056/NEJMoa2001017 [ Links ]
Liya G, Yuguang W, Jian L, Huaiping Y, Xue H, Jianwei H, et al. Studies on viral pneumonia related to novel coronavirus SARS-CoV-2, SARS-CoV, and MERS-CoV: a literature review. APMIS. 2020;128(6):423-32. https://doi.org/10.1111/apm.13047 [ Links ]
Wu Z, McGoogan JM. Characteristics of and important lessons from the Coronavirus Disease 2019 (COVID-19) outbreak in China: summary of a Report of 72 314 cases from the Chinese Center for Disease Control and Prevention. JAMA. 2020;323(13):1239-42. https://doi.org/10.1001/jama.2020.2648 [ Links ]
Horton R. Offline: COVID-19 is not a pandemic. Lancet. 2020;396(10255):874. https://doi.org/10.1016/S0140-6736(20)32000-6 [ Links ]
Adhikari SP, Meng S, Wu YJ, Mao YP, Ye RX, Wang QZ, et al. Epidemiology, causes, clinical manifestation and diagnosis, prevention and control of coronavirus disease (COVID-19) during the early outbreak period: a scoping review. Infect Dis Poverty. 2020;9(1):29. https://doi.org/10.1186/s40249-020-00646-x [ Links ]
Choudhary S, Sreenivasulu K, Mitra P, Misra S, Sharma P. Role of genetic variants and gene expression in the susceptibility and severity of COVID-19. Ann Lab Med. 2021;41(2):129-38. https://doi.org/10.3343/alm.2021.41.2.129 [ Links ]
Practice BB. Coronavirus disease 2019. Geneva: WHO; 2019 [cited 2020 Apr 5):2633. Available from: https://www.who.int/emergencies/diseases/novel-coronavirus-2019 [ Links ]
Ministério da Saúde (BR), Secretaria de Vigilância em Saúde. Painel Coronavírus. [cited 2020 Mar 26]. Available from: https://covid.saude.gov.br/ [ Links ]
Huang C, Wang Y, Li X, Ren L, Zhao J, Hu Y, et al. Clinical features of patients infected with 2019 novel coronavirus in Wuhan, China. Lancet. 2020;395(10223):497-506. https://doi.org/10.1016/S0140-6736(20)30183-5 [ Links ]
Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Imunização e Doenças Transmissíveis, Coordenação Geral do Programa Nacional de Imunizações. Plano Nacional de Operacionalização da Vacinação contra a Covid-19. Brasil Imunizado Somos Uma Só Nação 2020. Brasília, DF; 2020 [cited 2021 Mar 20]. Available from: https://www.gov.br/saude/pt-br/media/pdf/2021/marco/23/plano-nacional-de-vacinacao-covid-19-de-2021 [ Links ]
Ministério da Saúde da Saúde (BR), Secretaria de Vigilância em Saúde Agência Nacional de Vigilância Sanitária. Estratégia de Vacinação contra o Vírus SARS-CoV-2 COVID-19: Protocolo de Vigilância Epidemiológica e Sanitária de Eventos Adversos Pós-Vacinação 2020. Brasília, DF; 2020 [cited 2021 Mar 20]. Available from: https://www.gov.br/saude/pt-br/media/pdf/2020/dezembro/21/estrategia_vacinacao_covid19.pdf [ Links ]
World Health Organization; Council for International Organizations of Medical Sciences. Definition and application of terms for vaccine pharmacovigilance: report of CIOMS/WHO Work Group on Vaccine Pharmacovigilance. Geneva: WHO/CIOMS; 2012. [ Links ]
Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Imunizações e Doenças Transmissíveis. Manual de Vigilância Epidemiológica de Eventos Adversos Pós-Vacinação. Brasília, DF; 2020 [cited 2021 Jul 22]. [ Links ]
Ministério da Saúde (BR). e-SUS Notifica. Available from: https://notifica.saude.gov.br/login. [ Links ]
Xing K, Tu XY, Liu M, Liang ZW, Chen JN, Li JJ, et al. Efficacy and safety of COVID-19 vaccines: a systematic review. Zhongguo Dang Dai Er Ke Za Zhi. 2021;23(3):221-8. https://doi.org/10.7499/j.issn.1008-8830.2101133 [ Links ]
Domingues CMAS, Maranhão AGK, Teixeira AM, Fantinato FFS, Domingues RAS. The Brazilian National Immunization Program: 46 years of achievements and challenges. Cad Saude Publica. 2020;36 Supl 2:e00222919. https://doi.org/10.1590/0102-311X00222919 [ Links ]
Knoll MD, Wonodi C. Oxford-AstraZeneca COVID-19 vaccine efficacy. Lancet. 2021;397(10269):72-4. https://doi.org/10.1016/S0140-6736(20)32623-4 [ Links ]
Ranzani OT, Bastos LSL, Gelli JGM, Marchesi JF, Baião F, Hamacher S, et al. Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data. Lancet Respir Med. 2021;9(4):407-18. https://doi.org/10.1016/S2213-2600(20)30560-9 [ Links ]
Kwok KO, Lai F, Wei WI, Wong SYS, Tang JWT. Herd immunity - estimating the level required to halt the COVID-19 epidemics in affected countries. J Infect. 2020;80(6):e32-3. https://doi.org/10.1016/j.jinf.2020.03.027 [ Links ]
Instituto Brasileiro de Geografia e Estatística. Áreas territoriais. Rio de Janeiro: IBGE; 2019 [cited 2020 Dec 21]. Available from: https://www.ibge.gov.br/geociencias/organizacao-do-territorio/estrutura-territorial/15761-areas-dos-municipios.html [ Links ]
Instituto Brasileiro de Geografia e Estatística, Coordenação de População e Indicadores Sociais. Estimativas da população residente no Brasil e unidades da federação com data de referência em 1º de julho de 2019. Rio de Janeiro: IBGE; 2019 [cited 2020 Dec 21]. Available from: https://biblioteca.ibge.gov.br/index.php/biblioteca-catalogo?view=detalhes&id=2101662 [ Links ]
Ministério da Saúde (BR), Secretária de Vigilância em Saúde. Situação epidemiológica dos eventos adversos pós-vacinação contra a covid-19, Brasil, 2021. Bol Epidemiol. 202;52(9):1-7. [ Links ]
Voysey M, Clemens SAC, Madhi SA, Weckx LY, Folegatti PM, Aley PK, et al. Single-dose administration and the influence of the timing of the booster dose on immunogenicity and efficacy of ChAdOx1 nCoV-19 (AZD1222) vaccine: a pooled analysis of four randomised trials. Lancet. 2021;397(10277):881-91. https://doi.org/10.1016/S0140-6736(21)00432-3 [ Links ]
Palacios R, González Patiño E, Piorelli RO, Conde MTRP, Batista AP, Zeng G, et al. Double-blind, randomized, placebo-controlled phase III clinical trial to evaluate the efficacy and safety of treating healthcare professionals with the adsorbed COVID-19 (inactivated) vaccine manufactured by Sinovac - PROFISCOV: a structured summary of a study protocol for a randomised controlled trial. Trials. 2020;21(1):853. https://doi.org/10.1186/s13063-020-04775-4 [ Links ]
Maria Helena Machado, coordenadora. Perfil da Enfermagem no Brasil: relatório final. Rio de Janeiro: Fiocruz/COFEN; 2017. [ Links ]
Secretaria de Estado de Saúde de Minas Gerais. Vacinômetro. Belo Horizonte: SES-MG; 2021 [cited 2021 Mar 5]. Available from: https://coronavirus.saude.mg.gov.br/vacinometro [ Links ]
World Health Organization. GACVS COVID-19 Vaccine Safety subcommittee meeting to review reports of deaths of very frail elderly individuals vaccinated with Pfizer BioNTech COVID-19 vaccine, BNT162b2. Geneva: WHO; 2021 [cited 2021 Feb 22]. Available from: https://www.who.int/news/item/22-01-2021-gacvs-review-deaths-pfizer-biontech-covid-19-vaccine-bnt162b2 [ Links ]
Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Imunização e Doenças Transmissíveis, Coordenação-Geral do Programa Nacional de Imunizações. Nota Informativa Nº 11/2021-CGPNI/DEIDT/SVS/MS. Esclarecimentos sobre eventos adversos supostamente atribuíveis à vacinação contra a covid-19. Brasilia, DF; 2021 [cited 2021 Apr 6]. Available from: https://www.gov.br/saude/pt-br/media/pdf/2021/fevereiro/05/nota-informativa-esclarecimentos-sobre-eventos-adversos-covid-19.pdf [ Links ]
Bisetto LHL, Ciosak SI. Análise da ocorrência de evento adverso pós-vacinação decorrente de erro de imunização. Rev Bras Enferm. 2017;70(1):87-95. [ Links ]
Monteiro SAMG, Takano OA, Waldman EA. Avaliação do sistema brasileiro de vigilância de eventos adversos pós-vacinação. Rev Bras Epidemiol. 2011;14(3):361-71. https://doi.org/10.1590/S1415-790X2011000300002 [ Links ]
Ministério da Saúde (BR), Secretaria de Vigilância em Saúde, Departamento de Imunização e Doenças Transmissíveis, Coordenação-Geral do Programa Nacional de Imunizações. Nota Informativa Nº 21/2021-CGPNI/DEIDT/SVS/MS. Orientações referentes aos erros de imunização relacionados às vacinas COVID-19. Brasilia, DF; 2021 [cited 2021 Apr 6]. Available from: http://vigilancia.saude.mg.gov.br/index.php/download/nota-informativa-no-21-2021-cgpni-deidt-svs-ms-orientacoes-referentes-aos-erros-de-imunizacao-relacionados-as-vacinas-covid-19/?wpdmdl=8463 [ Links ]
Gray KJ, Bordt EA, Atyeo C, Deriso E, Akinwunmi B, Young N, et al. COVID-19 vaccine response in pregnant and lactating women: a cohort study. Am J Obstet Gynecol. 2021. https://doi.org/10.1016/j.ajog.2021.03.023 [ Links ]
Ministério da Saúde (BR), Secretaria de Atenção Primária à Saúde, Departamento de Açõe Programáticas Estratégicas. Nota Técnica Nº 1/2021-DAPES/SAPS/MS. Recomendações referentes a administração de vacinas covid 19 em gestantes, puérperas e lactantes, incluindo os esclarecimentos que devem ser fornecidos para tomada de decisão. Brasilia, DF; 2021 [cited 2021 Apr 6]. Available from: http://vigilancia.saude.mg.gov.br/index.php/download/nota-tecnica-no-01-2021-ms-tratam-se-das-recomendacoes-referentes-a-administracao-de-vacinas-covid-19-em-gestantes-puerperas-e-lactantes/?wpdmdl=8507 [ Links ]
Takemoto MLS, Menezes MO, Andreucci CB, Nakamura-Pereira M, Amorim MMR, Katz L, et al. The tragedy of COVID-19 in Brazil: 124 maternal deaths and counting. Int J Gynaecol Obstet. 2020;151(1):154-6. https://doi.org/10.1002/ijgo.13300 [ Links ]
Downloads
Published
Issue
Section
License
Copyright (c) 2021 Roberta Barros da Silva, Thales Philipe Rodrigues da Silva, Ana Paula Sayuri Sato, Francisco Carlos Felix Lana, Josianne Dias Gusmão, Janaina Fonseca Almeida Souza, Fernanda Penido Matozinhos
This work is licensed under a Creative Commons Attribution 4.0 International License.
